Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its position in Arvinas, Inc. (NASDAQ:ARVN) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 530,669 shares of the company’s stock after selling 13,834 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.77% of Arvinas worth $13,070,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ARVN. SG Americas Securities LLC grew its position in Arvinas by 137.2% during the second quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock worth $2,292,000 after buying an additional 49,799 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in shares of Arvinas by 6.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 65,907 shares of the company’s stock worth $1,754,000 after purchasing an additional 4,045 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Arvinas by 32.6% in the second quarter. Bank of New York Mellon Corp now owns 235,096 shares of the company’s stock worth $6,258,000 after acquiring an additional 57,835 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Arvinas by 13.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 14,298 shares of the company’s stock worth $381,000 after buying an additional 1,728 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Arvinas by 30.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,062 shares of the company’s stock worth $268,000 after purchasing an additional 2,363 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Stock Up 4.8 %

Arvinas stock opened at $25.92 on Monday. The stock has a market cap of $1.78 billion, a P/E ratio of -5.55 and a beta of 1.82. Arvinas, Inc. has a 12 month low of $21.17 and a 12 month high of $53.08. The company’s fifty day simple moving average is $25.76 and its 200-day simple moving average is $26.40.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to the consensus estimate of $60.56 million. During the same period in the previous year, the business posted ($1.18) EPS. Arvinas’s revenue was up 196.0% compared to the same quarter last year. On average, equities research analysts expect that Arvinas, Inc. will post -3.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ARVN shares. Oppenheimer reduced their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. BMO Capital Markets decreased their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Monday, September 9th. Stephens began coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $87.00 target price on shares of Arvinas in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.